A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus

International Journal of Clinical Practice

Volumn 69, Issue 6, 2015, Pages 626-631

  Shankar, Ravi R ^a   Xu, L ^a   Golm, G T ^a   O'neill, E A ^a   Goldstein, B J ^b   Kaufman, K D ^a   Engel, S S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b 206 Carnegie Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED;

AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SITAGLIPTIN PHOSPHATE; SULFONYLUREA COMPOUNDS;

EID: 84930045169     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12607     Document Type: Article

References (31)

1. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels: International Diabetes Federation, 2013.
2. Kinsella K, Velkoff VA,. An Aging World. Washington, DC: Government Printing Office, 2001.
3. Perry HM III,. The endocrinology of aging. Clin Chem 1999; 45: 1369-76.
4. Gregg EW, Cheng YJ, Saydah S, et al., Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. Diabetes Care 2012; 35: 1252-7.
5. Wild S, Roglic G, Green A, Sicree R, King H,. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
6. Nathan DM, Singer DE, Godine JE, Harrington CH, Perlmuter LC,. Retinopathy in older type II diabetics. Association with glucose control. Diabetes 1986; 35: 797-801.
7. Holstein A, Hammer C, Hahn M, Kulamadayil NS, Kovacs P,. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf 2010; 9: 675-81.
8. Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B,. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009; 32: 1513-7.
9. Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschope D,. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol 2012; 11: 122.
10. Holstein A, Egberts EH,. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111: 405-14.
11. Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D,. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008; 10 (Suppl. 1): 16-24.
12. Meneilly GS, Cheung E, Tuokko H,. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994; 43: 403-10.
13. Deusenberry CM, Coley KC, Korytkowski MT, Donihi AC,. Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy 2012; 32: 613-7.
14. Mazza AD, Morley JE,. Update on diabetes in the elderly and the application of current therapeutics. J Am Med Dir Assoc 2007; 8: 489-92.
15. Herman GA, Stein PP, Thornberry NA, Wagner JA,. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007; 81: 761-7.
16. Arechavaleta R, Seck T, Chen Y, et al., Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011; 13: 160-8.
17. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G,. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-43.
18. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP,. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
19. Raz I, Chen Y, Wu M, et al., Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008; 24: 537-50.
20. Reasner C, Olansky L, Seck TL, et al., The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13: 644-52.
21. Scott R, Loeys T, Davies MJ, Engel SS,. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 959-69.
22. Seck T, Nauck M, Sheng D, et al., Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64: 562-76.
23. Williams-Herman D, Johnson J, Teng R, et al., Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009; 25: 569-83.
24. Williams-Herman D, Johnson J, Teng R, et al., Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 442-51.
25. Henry RR, Staels B, Fonseca VA, et al., Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone-a factorial study. Diabetes Obes Metab 2014; 16: 223-30. doi: 10.1111/dom.12194.
26. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P,. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28: 1556-68.
27. Scott R, Wu M, Sanchez M, Stein P,. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007; 61: 171-80.
28. Miettinen O, Nurminen M,. Comparative analysis of two rates. Stat Med 1985; 4: 213-26.
29. Panten U, Schwanstecher M, Schwanstecher C,. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes 1996; 104: 1-9.
30. Barnett AH,. Complementing insulin therapy to achieve glycemic control. Adv Ther 2013; 30: 557-76.
31. Segel SA, Paramore DS, Cryer PE,. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002; 51: 724-33.